Navigation Links
Hospira's Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval
Date:10/18/2007

- Approval and Launch of Hospira's First Similar Biologic Expected by Early

2008 -

LAKE FOREST, Ill., Oct. 19 /PRNewswire-FirstCall/ -- Hospira (NYSE: HSP), a leading global hospital products company, announced today that it has received a "positive opinion" recommending European Union (EU) approval for Retacrit (epoetin zeta), a treatment for anemia associated with chronic renal failure and chemotherapy-induced anemia. Retacrit is a similar biologic -- often referred to as a "biosimilar" in Europe or "biogeneric" in the United States -- to epoetin alfa.

The Committee for Medicinal Products for Human Use (CHMP) issued the positive opinion; and the European Commission, which approves pharmaceuticals, usually follows CHMP recommendations. Hospira expects EU approval for Retacrit in late 2007. The company plans to launch the product -- which will be Hospira's first marketed similar biologic -- in various EU countries beginning in early 2008.

"As the world leader in generic injectables, Hospira is ready to bring high-quality, lower-cost similar biologics to patients. We are pleased to have crossed this milestone for this important medication," says Michael Kotsanis, president, Europe, Middle East and Africa, Hospira. "Similar biologics like Retacrit can help provide safe, effective patient care while helping to reduce global healthcare costs."

In late 2006 Hospira; STADA Arzneimittel AG; and BIOCEUTICALS Arzneimittel AG, a STADA-initiated company, announced development, manufacturing and distribution agreements for epoetin zeta. Under these agreements, Hospira obtained exclusive distribution rights for the product in countries including the United States and much of Europe, with the exception of Germany, where Hospira and STADA will both market the product. The epoetin zeta project is being pursued through BIOCEUTICALS. STADA controlled the development process and conducted the approval process on behalf o
'/>"/>

SOURCE Hospira, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Lucigen receives $750K grant to boost biofuel yields
3. Medical College receives $1.4M cancer grant
4. Wisconsin biotech firm receives $107K NIH grant
5. InvivoSciences receives NIH grant for heart technology
6. Medical College receives $11 million grant to study high blood pressure
7. Madison business receives $115,000 of new state biofuels funding
8. Superior receives funds for technical training
9. UWM receives state funding for plastics research
10. GEs Centricity EHR receives federal certification
11. WHIE receives state eHealth Initiative contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 1, 2015 Investor-Edge has ... Ltd (NASDAQ: GENE ), Agilent Technologies Inc. ... (NYSE: TMO ), Sequenom Inc. (NASDAQ: ... ). Free research report on Genetic Technologies can ... April 30, 2015, the NASDAQ Composite ended at ...
(Date:4/30/2015)... 2015  Roka Bioscience, Inc. (NASDAQ: ROKA ), ... solutions for the detection of foodborne pathogens, announced plans ... of 2015 on May 7, 2015 after the close ... also host a conference call at 4:30 p.m. Eastern ... quarter financial results. During the conference call, material information ...
(Date:4/30/2015)... , April 30, 2015 Oxford Finance ... debt to life sciences and healthcare services companies, today ... term loan agreement with Celula, Inc., a diagnostic testing ... diseases, enabling better patient care and improved outcomes.  Proceeds ... development and expand the commercialization of its products in ...
(Date:4/30/2015)... MENLO PARK, Calif. , April 30, 2015 /PRNewswire/ ... company in the emerging field of regenerative medicine, today ... operating results on Thursday, May 7, 2015 after the ... host a conference call and webcast on Thursday, May ... Pacific to discuss the results and recent corporate developments. ...
Breaking Biology Technology:Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2Oxford Finance Provides $10 Million Debt Financing to Celula 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3
... April 1 Nutrition 21, Inc. (Nasdaq: ... that help consumers manage blood sugar levels, improve cardiovascular ... today that on March 31, 2009 it redeemed all ... required by the terms of these shares. The Company ...
... and Saint Joseph,s Hospital Team UpATLANTA, April 1 ... have joined together to begin the first regional research ... pancreatic cancer. Tissue and serum samples from patients ... in genetic and cellular features between normal and tumor ...
... to prior yearROCHESTER, N.Y., April 1 VirtualScopics, Inc. ... quantitative imaging for clinical trials, today announced that its ... its active and awarded projects and commonly referred to ... million which compares to $13.7 million at the same ...
Cached Biology Technology:Nutrition 21 Redeems Series I Convertible Preferred Shares 2Nutrition 21 Redeems Series I Convertible Preferred Shares 3Groundbreaking Research Begins for Pancreatic and Lung Cancers 2Groundbreaking Research Begins for Pancreatic and Lung Cancers 3VirtualScopics' Project Balance Exceeds a Record $31 Million 2VirtualScopics' Project Balance Exceeds a Record $31 Million 3
(Date:3/24/2015)... March 24, 2015   NexID Biometrics LLC, ... security-authentication needs, today announced the beginning of shipments of ... The company, based in Potsdam, ... three-day Connect:ID Expo, which began here today at the ... version 2.0 of its SDK boosts the accuracy rate ...
(Date:3/23/2015)... 23, 2015 SoundView Technology Group issues a new ... NXTD ) Wocket smart wallet. SoundView was one of the selected ... experience with the Wocket in multiple scenarios and outlets. ... and other retailers, making both debit and credit card payments.  ... says, "If the company meets their plans in 2015, it ...
(Date:3/23/2015)... ANGELES , March 23, 2015  In the ... Federal fraud case conviction losses. This figure accounts for ... which, according to The Nilson Report, exceeds $11 billion ... investigative tool after a crime has occurred. Investor ... and polygraph expert Joe Paolella partnered to ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... Thirty to fifty percent of the global conversion of nutrients ... of the National Academy of Science of the United States ... state that this conversion is not carried out by denitrifying ... Nitrogen compounds act as fertilizers and are the ecological basis ...
... with variant Creutzfeldt-Jakob (vCJD) prions may no longer be ... a transfusion. Pall Corporation (NYSE: PLL) announced today the ... Prion Reduction Filter System. It is the first and ... the causative agent of vCJD from red cells, the ...
... only three months after deciding to create an ... trial registry and results database using an independent ... trials can be accessed by anyone, anywhere, with ... give patients and healthcare providers ready access to ...
Cached Biology News:Anammox bacteria produce nitrogen gas in oceans' snackbar 2Anammox bacteria produce nitrogen gas in oceans' snackbar 3First technology to remove prions that cause vCJD from blood launched 2First technology to remove prions that cause vCJD from blood launched 3First technology to remove prions that cause vCJD from blood launched 4Roche clinical trial registry and results database launched 2Roche clinical trial registry and results database launched 3
... Immunogen: Synthetic phosphopeptide corresponding to ... Ser603 residue of rat Synapsin ... synapsin I when phosphorylated at ... Rat (positive control: rat brain ...
EMBP (FL-222)...
... does not share significant homology with ... is expressed in the central nervous ... stomach. One important role PEBP ... activity against several serine proteases including ...
Anti-Rsk2/MAPKAP Kinase 1b, #0 SK2/MAPKAP K1 beta Smartpool&t 3T3 cell lysate Non-specific Control Pool , #D 1X Universal Buffer...
Biology Products: